Cue Biopharma (CUE) Assets (2017 - 2026)

Cue Biopharma has disclosed Assets across 10 years of filings, most recently posting $30.7 million for Q2 2026.

• In Q2 2026, Assets fell 24.57% year-over-year to $30.7 million; the TTM figure through Jun 2026 stood at $30.7 million (down 24.57% YoY), while the FY2025 annual figure was $42.2 million, up 31.13% from the prior year.
• Assets came in at $30.7 million for Q2 2026 at Cue Biopharma, down from $42.2 million in the prior quarter.
• In the past five years, Assets ranged from a high of $91.3 million in Q4 2022 to a low of $22.3 million in Q1 2025.
• Average Assets over 5 years is $57.0 million, with a median of $54.0 million recorded in 2024.
• The largest YoY upside for Assets was 31.13% in 2025 against a maximum downside of 58.75% in 2025.
• Over 5 years, Assets stood at $91.3 million in 2022, then sank by 32.59% to $61.5 million in 2023, then slumped by 47.68% to $32.2 million in 2024, then soared by 31.13% to $42.2 million in 2025, then fell by 27.26% to $30.7 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $30.7 million in Q2 2026, $42.2 million in Q4 2025, and $31.6 million in Q3 2025.